Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2022 07:50 ET | Source: Small Pharma Inc.

Small Pharma Shares Business Update Ahead of Annual Financial Results

- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting psychedelics portfolio LONDON, May 25, 2022 ...
May 05, 2022 07:50 ET | Source: Small Pharma Inc.

Small Pharma to Participate in the PSYCH Symposium: London 2022

LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
March 10, 2022 08:18 ET | Source: Small Pharma Inc.

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of...
March 09, 2022 14:46 ET | Source: Small Pharma Inc.

Small Pharma to Participate in the 34th Annual Roth Conference

LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuroscience company focused on psychedelic-assisted therapies for mental...
February 22, 2022 08:30 ET | Source: Small Pharma Inc.

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects on the...
January 31, 2022 17:05 ET | Source: Small Pharma Inc.

Small Pharma Reports Fiscal Third Quarter 2021 Highlights

LONDON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted...
January 04, 2022 07:50 ET | Source: Small Pharma Inc.

Small Pharma to Attend Upcoming Healthcare Conferences in January 2022

LONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on...
December 01, 2021 08:49 ET | Source: Small Pharma Inc.

Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies,...
November 18, 2021 14:04 ET | Source: Small Pharma Inc.

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies,...
November 15, 2021 07:50 ET | Source: Small Pharma Inc.

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies...